血清miR-28-3p、miR-23a表达水平与非小细胞肺癌射频消融治疗患者预后的相关性

doi:10.3969/j.issn.1671-7171.2024.06.009

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1381 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the correlation between the expression levels of serum miR-28-3p and miR-23a and the prognosis of patients with non-small cell lung cancer(NSCLC) undergoing radiofrequency ablation(RFA) treatment.【Methods】A total of 94 NSCLC patients treated with RFA were included in the study. Based on the survival status of the patients during follow-up, they were divided into a survival group(74 cases) and a deceased group(20 cases). The serum levels of miR-28-3p and miR-23a were compared between the two groups. Spearman correlation was used to assess the relationship between serum miR-28-3p and miR-23a levels and the prognosis of the patients. Receiver operating characteristic(ROC) curves were constructed to analyze the predictive value of combined detection of serum miR-28-3p and miR-23a levels for patient prognosis.【Results】 The serum levels of miR-28-3p and miR-23a in the survival group were lower than those in the deceased group(P<0.05). Spearman analysis showed that serum miR-28-3p and miR-23a levels were positively correlated with poor prognosis in NSCLC patients(P<0.05). ROC analysis indicated that the combined detection of serum miR-28-3p and miR-23a levels had a sensitivity of 95.0% and a specificity of 97.3% for predicting patient prognosis, with an area under the curve(AUC) of 0.986, which was superior to the detection of each marker alone(P<0.05).【Conclusion】 The levels of serum miR-28-3p and miR-23a are positively correlated with poor prognosis in NSCLC patients treated with RFA. Combined detection of these two markers has high sensitivity and specificity for predicting patient prognosis.

Key words： Carcinoma, Non-Small-Cell Lung MicroRNAs/BL Radiofrequency Ablation Prognosis

Received: 10 February 2024

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FENG Yanliang
	LI Ye
	LI Hao

Cite this article:

FENG Yanliang,LI Ye,LI Hao. Correlation of Serum miR-28-3p and miR-23a Levels with Prognosis of Patients with Non-Small Cell Lung Cancer Treated with Radiofrequency Ablation[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 831-833.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.06.009 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I6/831

[1] 张殿宝,郝吉庆,张宪芬,等. LncRNA TUG1调控miR-142-5p/PD-L1轴促进非小细胞肺癌细胞增殖、迁移与侵袭能力[J].临床与实验病理学杂志,2023,39(3):297-304.
[2] 郄鹏,聂小栋,殷其凡,等. 射频消融术、胸腔镜部分肺切除术治疗Ⅰ期非小细胞肺癌对比观察[J].山东医药,2023,63(12):69-71.
[3] 崔凯,白峻峰,支亚男,等. 外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048-1051.
[4] 钱剑男,杨邵瑜,陈雪琴,等. 2022年第3版《NCCN非小细胞肺癌临床实践指南》更新解读[J].实用肿瘤杂志,2022,37(3):197-204.
[5] 刘芳,彭岚竹,席菁乐. 高表达MYH9通过激活AKT/c-Myc通路抑制非小细胞肺癌细胞凋亡[J].南方医科大学学报,2023,43(4):527-536.
[6] 刘继伟,杨瑞. 高分辨率CT引导下射频消融治疗早期非小细胞肺癌研究[J].实用放射学杂志,2023,39(6):1001-1004.
[7] 玉建勋,文宁,黎雪华,等. 探讨CT引导下射频消融治疗无法手术治疗的老年非小细胞肺癌患者的疗效及预后[J].肿瘤影像学,2023,32(3):269-274.
[8] 唐钢琴,赵振华,梁晓超. 非小细胞肺癌患者射频消融治疗后血清miR-28-3p表达量变化及意义[J].介入放射学杂志,2019,28(9):887-890.
[9] 郝艳萍,王光. 非小细胞肺癌患者血浆miR-499与miR-23a表达及其检测意义[J].临床肺科杂志,2018,23(2):199-202.
[10] 张藻,李立,杨倩,等. 非小细胞肺癌患者EGFR-TKIs耐药后射频消融治疗的疗效及预后分析[J].临床肺科杂志,2019,24(5):890-895.
[11] 乔玲,牛倩倩,郑梦瑶. 血清miR-28-3p、miR-23a与非小细胞肺癌射频消融治疗患者预后生存的关系[J].分子诊断与治疗杂志,2023,15(9):1574-1578.
[12] 汪波,李婷. 表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗联合CT引导下射频消融术对中晚期非小细胞肺癌患者的治疗效果[J].癌症进展,2023,21(2):221-224.
[13] 张吉瑞,汤佳琦,夏铀铀. miRNA在非小细胞肺癌诊断和治疗中的研究进展[J].癌症进展,2020,18(1):4-7.
[14] 李杰,刘天旭,吕微,等. miR-28-3p通过抑制BIN1表达促进三阴性乳腺癌MDA-MB-468细胞的恶性生物学行为[J].中国肿瘤生物治疗杂志,2020,27(1):55-61.